Obesity, Fatty Liver and Liver Cancer

Häftad, Engelska, 2019

Del 1061 i serien Advances in Experimental Medicine and Biology

1 659 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field.

Produktinformation

Utgivningsdatum:2019-02-06
Mått:178 x 254 x 10 mm
Vikt:381 g
Format:Häftad
Språk:Engelska
Serie:Advances in Experimental Medicine and Biology
Antal sidor:157
Förlag:Springer Verlag, Singapore
ISBN:9789811342134

Utforska kategorier

Onkologi inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin
Klinisk medicin och internmedicin inom Medicin

Mer om författaren

Prof. Jun Yu is Professor in Department of Medicine & Therapeutics, Director of Research Laboratory of Institute of Digestive Disease, Associate Director of State Key Laboratory of Digestive Disease and Faculty of Medicine in The Chinese University of Hong Kong.

Innehållsförteckning

Chapter 1. Introduction.- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC.- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease.- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD.- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders.- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack?.- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC.- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.- Chapter 9. Microbiota, obesity and NAFLD.- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC.- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer.- Chapter 12. Current prevention and treatment options for NAFLD.